Lehtomäki Kaisa, Soveri Leena-Maija, Osterlund Emerik, Lamminmäki Annamarja, Uutela Aki, Heervä Eetu, Halonen Päivi, Stedt Hanna, Aho Sonja, Muhonen Timo, Ålgars Annika, Salminen Tapio, Kallio Raija, Nordin Arno, Aroviita Laura, Nyandoto Paul, Kononen Juha, Glimelius Bengt, Ristamäki Raija, Isoniemi Helena, Osterlund Pia
Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön Katu 34, 33520 Tampere, Finland.
Department of Oncology, Tays Cancer Centre, Tampere University Hospital, Teiskontie 35, 33520 Tampere, Finland.
J Clin Med. 2023 May 18;12(10):3541. doi: 10.3390/jcm12103541.
Older adults are underrepresented in metastatic colorectal cancer (mCRC) studies and thus may not receive optimal treatment, especially not metastasectomies. The prospective Finnish real-life RAXO-study included 1086 any organ mCRC patients. We assessed repeated centralized resectability, overall survival (OS), and quality of life (QoL) using 15D and EORTC QLQ-C30/CR29. Older adults (>75 years; n = 181, 17%) had worse ECOG performance status than adults (<75 years, n = 905, 83%), and their metastases were less likely upfront resectable. The local hospitals underestimated resectability in 48% of older adults and in 34% of adults compared with the centralized multidisciplinary team (MDT) evaluation ( < 0.001). The older adults compared with adults were less likely to undergo curative-intent R0/1-resection (19% vs. 32%), but when resection was achieved, OS was not significantly different (HR 1.54 [CI 95% 0.9-2.6]; 5-year OS-rate 58% vs. 67%). 'Systemic therapy only' patients had no age-related survival differences. QoL was similar in older adults and adults during curative treatment phase (15D 0.882-0.959/0.872-0.907 [scale 0-1]; GHS 62-94/68-79 [scale 0-100], respectively). Complete curative-intent resection of mCRC leads to excellent survival and QoL even in older adults. Older adults with mCRC should be actively evaluated by a specialized MDT and offered surgical or local ablative treatment whenever possible.
老年患者在转移性结直肠癌(mCRC)研究中的代表性不足,因此可能无法接受最佳治疗,尤其是无法接受转移灶切除术。前瞻性芬兰真实世界RAXO研究纳入了1086例任何器官转移的mCRC患者。我们使用15D和欧洲癌症研究与治疗组织生活质量问卷核心30项/结直肠癌模块29项(EORTC QLQ-C30/CR29)评估了重复的集中可切除性、总生存期(OS)和生活质量(QoL)。老年患者(>75岁;n = 181,17%)的东部肿瘤协作组(ECOG)体能状态比成年患者(<75岁,n = 905,83%)更差,且他们的转移灶前期可切除的可能性更小。与集中多学科团队(MDT)评估相比,当地医院低估了48%的老年患者和34%的成年患者的可切除性(P<0.001)。与成年患者相比,老年患者接受根治性意图R0/1切除的可能性更小(19%对32%),但当实现切除时,总生存期无显著差异(风险比1.54[95%置信区间0.9 - 2.6];5年总生存率58%对67%)。“仅接受系统治疗”的患者没有年龄相关的生存差异。在根治性治疗阶段,老年患者和成年患者的生活质量相似(15D评分分别为0.882 - 0.959/0.872 - 0.907[0 - 1量表];全球健康状况评分分别为62 - 94/68 - 79[0 - 100量表])。mCRC的根治性意图完全切除即使对老年患者也能带来良好的生存和生活质量。mCRC老年患者应由专业的MDT进行积极评估,并尽可能提供手术或局部消融治疗。